BioCentury | Sep 14, 2015
Company News

R-Tech Ueno, Sucampo deal

...for the fiscal year ended March 31. The deal is expected to close in 4Q15. R-Tech Ueno Ltd....
BioCentury | Aug 27, 2015
Company News

Sucampo launches tender offer to acquire R-Tech Ueno

...Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) launched a tender offer to acquire R-Tech Ueno Ltd. (JASDAQ:4573) for Y33 billion ($273.9...
BioCentury | Jun 22, 2015
Company News

R-Tech Ueno Ltd, Hokkaido University deal

...under the deal and said it plans to license the compound following a proof-of-concept study. R-Tech Ueno...
BioCentury | Jun 8, 2015
Company News

Santen, R-Tech Ueno deal

...details, and Santen did not responds to inquiries. Santen Pharmaceutical Co. Ltd. (Tokyo:4536), Osaka, Japan R-Tech Ueno Ltd....
BioCentury | Apr 20, 2015
Finance

Liking Japan's retail exodus

...Takeda said a regulatory setback for 3-D Matrix Ltd. (JASDAQ:7777) and a clinical setback for R-Tech Ueno Ltd....
BioCentury | Mar 16, 2015
Company News

R-Tech Ueno, Sucampo deal

...of Japan, Korea, Taiwan and China under an amended 2009 deal (see BioCentury, March 2). R-Tech Ueno Ltd....
BioCentury | Mar 16, 2015
Clinical News

Unoprostone isopropyl: Phase III data

...commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China under an amended 2009 deal. R-Tech Ueno Ltd....
BioCentury | Mar 2, 2015
Company News

R-Tech Ueno, Sucampo, Par Pharmaceutical ophthalmic news

...from R-Tech to develop and commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China. R-Tech Ueno Ltd....
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial...
BioCentury | Dec 22, 2014
Clinical News

Rescula unoprostone isopropyl regulatory update

...Japan granted Orphan Drug designation to unoprostone isopropyl from R-Tech Ueno to treat retinitis pigmentosa (RP). The...
...commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China (see BioCentury, March 25, 2013). R-Tech Ueno Ltd....
Items per page:
1 - 10 of 38
BioCentury | Sep 14, 2015
Company News

R-Tech Ueno, Sucampo deal

...for the fiscal year ended March 31. The deal is expected to close in 4Q15. R-Tech Ueno Ltd....
BioCentury | Aug 27, 2015
Company News

Sucampo launches tender offer to acquire R-Tech Ueno

...Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) launched a tender offer to acquire R-Tech Ueno Ltd. (JASDAQ:4573) for Y33 billion ($273.9...
BioCentury | Jun 22, 2015
Company News

R-Tech Ueno Ltd, Hokkaido University deal

...under the deal and said it plans to license the compound following a proof-of-concept study. R-Tech Ueno...
BioCentury | Jun 8, 2015
Company News

Santen, R-Tech Ueno deal

...details, and Santen did not responds to inquiries. Santen Pharmaceutical Co. Ltd. (Tokyo:4536), Osaka, Japan R-Tech Ueno Ltd....
BioCentury | Apr 20, 2015
Finance

Liking Japan's retail exodus

...Takeda said a regulatory setback for 3-D Matrix Ltd. (JASDAQ:7777) and a clinical setback for R-Tech Ueno Ltd....
BioCentury | Mar 16, 2015
Company News

R-Tech Ueno, Sucampo deal

...of Japan, Korea, Taiwan and China under an amended 2009 deal (see BioCentury, March 2). R-Tech Ueno Ltd....
BioCentury | Mar 16, 2015
Clinical News

Unoprostone isopropyl: Phase III data

...commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China under an amended 2009 deal. R-Tech Ueno Ltd....
BioCentury | Mar 2, 2015
Company News

R-Tech Ueno, Sucampo, Par Pharmaceutical ophthalmic news

...from R-Tech to develop and commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China. R-Tech Ueno Ltd....
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial...
BioCentury | Dec 22, 2014
Clinical News

Rescula unoprostone isopropyl regulatory update

...Japan granted Orphan Drug designation to unoprostone isopropyl from R-Tech Ueno to treat retinitis pigmentosa (RP). The...
...commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China (see BioCentury, March 25, 2013). R-Tech Ueno Ltd....
Items per page:
1 - 10 of 38